946 related articles for article (PubMed ID: 1735956)
1. Regions with abundant neurofibrillary pathology in human brain exhibit a selective reduction in levels of binding-competent tau and accumulation of abnormal tau-isoforms (A68 proteins).
Bramblett GT; Trojanowski JQ; Lee VM
Lab Invest; 1992 Feb; 66(2):212-22. PubMed ID: 1735956
[TBL] [Abstract][Full Text] [Related]
2. Expression of tau mRNA and soluble tau isoforms in affected and non-affected brain areas in Alzheimer's disease.
Boutajangout A; Boom A; Leroy K; Brion JP
FEBS Lett; 2004 Oct; 576(1-2):183-9. PubMed ID: 15474035
[TBL] [Abstract][Full Text] [Related]
3. Predisposition to accelerated Alzheimer-related changes in the brains of human immunodeficiency virus negative opiate abusers.
Anthony IC; Norrby KE; Dingwall T; Carnie FW; Millar T; Arango JC; Robertson R; Bell JE
Brain; 2010 Dec; 133(Pt 12):3685-98. PubMed ID: 21126996
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical study of tau accumulation in early stages of Alzheimer-type neurofibrillary lesions.
Togo T; Akiyama H; Iseki E; Uchikado H; Kondo H; Ikeda K; Tsuchiya K; de Silva R; Lees A; Kosaka K
Acta Neuropathol; 2004 Jun; 107(6):504-8. PubMed ID: 15024583
[TBL] [Abstract][Full Text] [Related]
5. Truncated tau protein as a new marker for Alzheimer's disease.
Novák M
Acta Virol; 1994 Jun; 38(3):173-89. PubMed ID: 7817900
[TBL] [Abstract][Full Text] [Related]
6. Carboxyl-terminal fragments of presenilin-1 are closely related to cytoskeletal abnormalities in Alzheimer's brains.
Tomidokoro Y; Ishiguro K; Igeta Y; Matsubara E; Kanai M; Shizuka M; Kawarabayashi T; Harigaya Y; Kawakatsu S; Ii K; Ikeda M; St George-Hyslop PH; Hirai S; Okamoto K; Shoji M
Biochem Biophys Res Commun; 1999 Mar; 256(3):512-8. PubMed ID: 10080929
[TBL] [Abstract][Full Text] [Related]
7. [Alzheimer's disease: study of the distribution of tau proteins constituting helical filament pairs in human central nervous tissue].
Parent M; Delacourte A; Défossez A; Hémon B; Han KK; Petit H
C R Acad Sci III; 1988; 306(13):391-7. PubMed ID: 3136867
[TBL] [Abstract][Full Text] [Related]
8. Cytoskeletal alterations differentiate presenilin-1 and sporadic Alzheimer's disease.
Woodhouse A; Shepherd CE; Sokolova A; Carroll VL; King AE; Halliday GM; Dickson TC; Vickers JC
Acta Neuropathol; 2009 Jan; 117(1):19-29. PubMed ID: 19015863
[TBL] [Abstract][Full Text] [Related]
9. Properties of antigenic determinants that distinguish neurofibrillary tangles in progressive supranuclear palsy and Alzheimer's disease.
Schmidt ML; Lee VM; Hurtig H; Trojanowski JQ
Lab Invest; 1988 Oct; 59(4):460-6. PubMed ID: 2459498
[TBL] [Abstract][Full Text] [Related]
10. A peptidyl-prolyl isomerase, FKBP12, accumulates in Alzheimer neurofibrillary tangles.
Sugata H; Matsuo K; Nakagawa T; Takahashi M; Mukai H; Ono Y; Maeda K; Akiyama H; Kawamata T
Neurosci Lett; 2009 Aug; 459(2):96-9. PubMed ID: 19414059
[TBL] [Abstract][Full Text] [Related]
11. Neurofibrillary pathology and aluminum in Alzheimer's disease.
Shin RW; Lee VM; Trojanowski JQ
Histol Histopathol; 1995 Oct; 10(4):969-78. PubMed ID: 8574016
[TBL] [Abstract][Full Text] [Related]
12. Abnormally phosphorylated tau protein in senile dementia of Lewy body type and Alzheimer disease: evidence that the disorders are distinct.
Strong C; Anderton BH; Perry RH; Perry EK; Ince PG; Lovestone S
Alzheimer Dis Assoc Disord; 1995; 9(4):218-22. PubMed ID: 8749611
[TBL] [Abstract][Full Text] [Related]
13. Axonal disruption and aberrant localization of tau protein characterize the neuropil pathology of Alzheimer's disease.
Kowall NW; Kosik KS
Ann Neurol; 1987 Nov; 22(5):639-43. PubMed ID: 3122646
[TBL] [Abstract][Full Text] [Related]
14. An aluminum-based rat model for Alzheimer's disease exhibits oxidative damage, inhibition of PP2A activity, hyperphosphorylated tau, and granulovacuolar degeneration.
Walton JR
J Inorg Biochem; 2007 Sep; 101(9):1275-84. PubMed ID: 17662457
[TBL] [Abstract][Full Text] [Related]
15. Biochemical and anatomical redistribution of tau protein in Alzheimer's disease.
Mukaetova-Ladinska EB; Harrington CR; Roth M; Wischik CM
Am J Pathol; 1993 Aug; 143(2):565-78. PubMed ID: 8342603
[TBL] [Abstract][Full Text] [Related]
16. 14-3-3 proteins and zeta isoform containing neurofibrillary tangles in patients with Alzheimer's disease.
Umahara T; Uchihara T; Tsuchiya K; Nakamura A; Iwamoto T; Ikeda K; Takasaki M
Acta Neuropathol; 2004 Oct; 108(4):279-86. PubMed ID: 15235803
[TBL] [Abstract][Full Text] [Related]
17. Molecular dissection of the neurofibrillary lesions of Alzheimer's disease.
Goedert M
Arzneimittelforschung; 1995 Mar; 45(3A):403-9. PubMed ID: 7763334
[TBL] [Abstract][Full Text] [Related]
18. The possible role of capillary cerebral amyloid angiopathy in Alzheimer lesion development: a regional comparison.
Jeynes B; Provias J
Acta Neuropathol; 2006 Oct; 112(4):417-27. PubMed ID: 16830133
[TBL] [Abstract][Full Text] [Related]
19. Non-tau based neuronal degeneration in Alzheimer's disease -- an immunocytochemical and quantitative study in the supragranular layers of the middle temporal neocortex.
van de Nes JA; Nafe R; Schlote W
Brain Res; 2008 Jun; 1213():152-65. PubMed ID: 18455153
[TBL] [Abstract][Full Text] [Related]
20. Tau protein immunoreactivity in dementia of the Alzheimer type: II. Electron microscopy and pathogenetic implications. Effects of fixation on the morphology of the Alzheimer's abnormal filaments.
Papasozomenos SC
Lab Invest; 1989 Mar; 60(3):375-89. PubMed ID: 2494388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
